QUALITY MANAGEMENT SYSTEM
ISO9001 NATA CERTIFIED

SOLBEC PHARMACEUTICALS LTD
ACN 081 889 218
ABN 85 081 889 218

26 April 2006

Extension of Deadline – Share Purchase Plan

Dear Shareholder,

The Company's Directors advise that the Closing Date to participate in the Share Purchase Plan ("SPP") has been extended to **12 May 2006**.

The Directors considered the extension was sensible due to the number of public holidays occurring during the term of the SPP and to afford every eligible shareholder equal opportunity to participate.

The SPP offers all eligible shareholders the opportunity to acquire new shares for 8.5 cents per share (representing a 12% discount to the weighted volume average of Solbec's shares 30 days prior to 22 March 2006) and will also allow those shareholders who have small parcels of shares to increase their share holding up to a marketable parcel. The following three options apply:

Offer A	$4,930.00	58,000 shares
Offer B	$2,500.00	30,000 shares
Offer C	$1,020.00	12,000 shares

The funds will be used to assist the Australian Phase II clinical trials for Coramsine® targeting late stage renal cell carcinoma and malignant melanoma.

To participate, your application form and funds should be sent to Computershare in the postage paid envelope to be received by Friday 12 May. If you require the package to be resent, call Computershare on 1300 557 010.

Should you require any further information on the company's activities, feel free to call David Sparling, Solbec's General Manager on +61 (08) 9446 7555.

Kind regards,

Anthony Kiernan
Chairman
Solbec Pharmaceuticals Ltd.

Unit 1, 298 Selby Street, OSBORNE PARK WA 6017 Postal: PO Box 2142 CHURCHLANDS WA 6018
Tel: +61 8 9446 7555 Fax: +61 8 9446 8777 Email: info@solbec.com.au Website: www.solbec.com.au